What is ClinChoice?
As a full-service global CRO, ClinChoice operates at the intersection of clinical research and pharmaceutical development. The company provides comprehensive support for the entire drug development lifecycle, from early-phase clinical trials to post-market surveillance. By integrating advanced data analytics with deep therapeutic expertise, ClinChoice enables biopharmaceutical companies to navigate complex regulatory landscapes. Their market position is defined by a commitment to quality and speed, which is essential for clients aiming to reduce time-to-market for novel therapeutics and medical technologies in an increasingly competitive global healthcare environment.
How much funding has ClinChoice raised?
ClinChoice has raised a total of $150M across 1 funding round:
Series E
$150M
Series E (2022): $150M with participation from Taikang Insurance Group, Legend Capital, and Sherpa Healthcare Partners
Key Investors in ClinChoice
Taikang Insurance Group
A prominent financial services conglomerate that integrates insurance, asset management, and medical care, providing significant institutional backing for healthcare-focused enterprises.
Legend Capital
A seasoned private equity firm with a focus on innovation and growth-stage enterprises, leveraging extensive experience in managing large-scale USD and RMB funds.
Sherpa Healthcare Partners
A specialized investment firm dedicated to the healthcare sector, providing strategic guidance and capital to companies driving advancements in medical research and clinical development.
What's next for ClinChoice?
With the infusion of capital from this major enterprise-level funding, ClinChoice is well-positioned to expand its global service capabilities and enhance its technological infrastructure. The strategic focus will likely shift toward deepening its presence in key international markets and investing in digital health solutions that streamline clinical trial management. As the company matures, this financial runway will support the acquisition of specialized talent and the development of proprietary platforms, further cementing its status as an indispensable partner for global life sciences firms seeking to optimize their research and development pipelines.
See full ClinChoice company page
